Rozsa Schlenker-Herceg

TL;DR: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintinganib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.

TL;DR: The results of this Phase 2 clinical study support further evaluation of anti-TNF-alpha therapy in severe, chronic, symptomatic sarcoidosis.

TL;DR: Treatment with golimumab did not demonstrate a favorable risk-benefit profile in this study population of patients with severe persistent asthma, and an unfavorable risk- benefit profile led to early discontinuation of study-agent administration after the Week-24 database lock.

TL;DR: Subjects with moderate to severe COPD did not benefit from treatment with infliximab and the impact of inflIXimab on malignancy risk in patients with COPD needs to be further elucidated.

TL;DR: Nintedanib has a beneficial effect on slowing disease progression in patients with IPF and the meta-analysis was generally consistent with the pooled analysis.